Volume 60, Issue 1 pp. 26-30
Research Article

Progressive transformation of germinal centers in children and adolescents: An intriguing cause of lymphadenopathy

Furqan Shaikh MD

Corresponding Author

Furqan Shaikh MD

Paediatric Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada

Division of Paediatric Haematology/Oncology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8.===Search for more papers by this author
Bo-Yee Ngan MD

Bo-Yee Ngan MD

Division of Pathology, Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada

Search for more papers by this author
Sarah Alexander MD

Sarah Alexander MD

Paediatric Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada

Search for more papers by this author
Ronald Grant MD

Ronald Grant MD

Paediatric Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada

Search for more papers by this author
First published: 15 June 2012
Citations: 29

Conflict of interest: Nothing to declare.

Abstract

Background

The clinical implications of a diagnosis of progressive transformation of germinal centers (PTGC) in children are not well known.

Methods

To better understand this entity, we conducted a retrospective review of all patients aged 0–18 years diagnosed with PTGC at our center between 1998 and 2010.

Results

Twenty-nine patients were identified. Median age at diagnosis was 11.5 years, and median duration of follow-up was 2.8 years. Thirteen patients (45%) had a single episode of PTGC with no other associated features. Five patients (17%) had recurrent PTGC. Four patients (14%) had PTGC associated with Hodgkin lymphoma (HL): one preceding, two concurrent, and one subsequently developed HL. The most commonly associated HL was nodular lymphocyte-predominant HL. Seven patients (24%) had PTGC associated with immune disorders, including lupus, Castleman disease, and probable autoimmune lymphoproliferative syndrome. Overall, 15 patients (52%) had more than one lymph node biopsy. The cumulative incidence of a second biopsy after a diagnosis of PTGC was 42.3% ± 12.2% at 4 years. PTGC was PET-avid in all four patients tested.

Conclusions

PTGC is a nonspecific manifestation of a variety of associated conditions. There is a small risk of subsequent HL, and a larger risk of requiring multiple biopsies for recurrent PTGC. The presence of an immune disorder should be considered in patients who present with generalized lymphadenopathy, splenomegaly, immune cytopenias, and/or progression to HL. Routine surveillance imaging may not be required. Future research should determine the optimal surveillance strategy for patients with PTGC and the indications for repeat biopsies. Pediatr Blood Cancer 2013; 60: 26–30. © 2012 Wiley Periodicals, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.